Vivace Therapeutics clinically validates a new mechanism, though its rival Ikena reckons more specificity is needed to avoid toxicity.
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Imjudo’s clinical development period was almost the longest of any drug in recent memory. Here are some others.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
An FDA advisory committee refuses to overlook the potential dangers of roxadustat, Fibrogen's novel anaemia pill, leaving partner Astrazeneca with a difficult…